

Kan Yonemori

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6044237/publications.pdf>

Version: 2024-02-01

48
papers

817
citations

516710

16
h-index

552781

26
g-index

49
all docs

49
docs citations

49
times ranked

1141
citing authors

#	ARTICLE	IF	CITATIONS
1	A Phase 1 Study of Sapanisertib (TAK-228) in East Asian Patients with Advanced Nonhematological Malignancies. <i>Targeted Oncology</i> , 2022, 17, 15-24.	3.6	7
2	Dose Escalation Data from the Phase 1 Study of the Liposomal Formulation of Eribulin (E7389-LF) in Japanese Patients with Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2022, 28, 1783-1791.	7.0	3
3	Lenvatinib plus pembrolizumab in Japanese patients with endometrial cancer: Results from Study 309/KEYNOTE-775. <i>Cancer Science</i> , 2022, 113, 3489-3497.	3.9	10
4	Tisotumab vedotin in Japanese patients with recurrent/metastatic cervical cancer: Results from the innovaTV 206 study. <i>Cancer Science</i> , 2022, 113, 2788-2797.	3.9	14
5	Pembrolizumab plus chemotherapy in Japanese patients with persistent, recurrent or metastatic cervical cancer: Results from KEYNOTE-826. <i>Cancer Science</i> , 2022, 113, 3877-3887.	3.9	11
6	Olaparib plus bevacizumab as maintenance therapy in patients with newly diagnosed, advanced ovarian cancer: Japan subset from the PAOLA-1/ENGOT-ov25 trial. <i>Journal of Gynecologic Oncology</i> , 2021, 32, e82.	2.2	6
7	First-in-human study of the cancer peptide vaccine TAS0313 in patients with advanced solid tumors. <i>Cancer Science</i> , 2021, 112, 1514-1523.	3.9	6
8	First-in-Human Phase 1 Study of MORAb-202, an Antibody-Drug Conjugate Comprising Farletuzumab Linked to Eribulin Mesylate, in Patients with Folate Receptor-1-Positive Advanced Solid Tumors. <i>Clinical Cancer Research</i> , 2021, 27, 3905-3915.	7.0	37
9	Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis. <i>Clinical Cancer Research</i> , 2021, 27, 3970-3979.	7.0	15
10	Highly sensitive fusion detection using plasma cell-free RNA in non-small cell lung cancers. <i>Cancer Science</i> , 2021, 112, 4393-4403.	3.9	21
11	Nivolumab Versus Gemcitabine or Pegylated Liposomal Doxorubicin for Patients With Platinum-Resistant Ovarian Cancer: Open-Label, Randomized Trial in Japan (NINJA). <i>Journal of Clinical Oncology</i> , 2021, 39, 3671-3681.	1.6	84
12	First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data. <i>PLoS ONE</i> , 2021, 16, e0257489.	2.5	8
13	Critical Appraisal of Adjuvant Platinum-Based Chemotherapy for Basal Subtype Triple-Negative Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy. <i>Journal of Clinical Oncology</i> , 2021, 39, JCO.21.01537.	1.6	1
14	Treatment Outcome of Second-Line Chemotherapy for Gynecologic Carcinosarcoma. <i>Oncology</i> , 2020, 98, 699-705.	1.9	9
15	BRCA1 promoter methylation in breast cancer patients is associated with response to olaparib/eribulin combination therapy. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 323-329.	2.5	9
16	Gene Alterations in Triple-Negative Breast Cancer Patients in a Phase I/II Study of Eribulin and Olaparib Combination Therapy. <i>Translational Oncology</i> , 2019, 12, 1386-1394.	3.7	7
17	A phase I/II trial of olaparib tablet in combination with eribulin in Japanese patients with advanced or metastatic triple-negative breast cancer previously treated with anthracyclines and taxanes. <i>European Journal of Cancer</i> , 2019, 109, 84-91.	2.8	19
18	A Comparative Study of Longitudinal Toxicities of Cytotoxic Drugs, Molecularly Targeted Agents, Immunomodulatory Drugs, and Cancer Vaccines. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 803-809.	4.7	3

#	ARTICLE	IF	CITATIONS
19	Anticancer Agent-Induced Life-Threatening Skin Toxicities: A Database Study of Spontaneous Reporting Data. <i>Oncologist</i> , 2019, 24, 266-272.	3.7	3
20	BRCA Gene Mutations and Poly(ADP-Ribose) Polymerase Inhibitors in Triple-Negative Breast Cancer. <i>Advances in Experimental Medicine and Biology</i> , 2017, 1026, 271-286.	1.6	14
21	Drug induced interstitial lung disease in oncology phase I trials. <i>Cancer Science</i> , 2016, 107, 1830-1836.	3.9	12
22	Safety and tolerability of the olaparib tablet formulation in Japanese patients with advanced solid tumours. <i>Cancer Chemotherapy and Pharmacology</i> , 2016, 78, 525-531.	2.3	21
23	Japanese universal health care faces a crisis in cancer treatment. <i>Lancet Oncology</i> , 2015, 16, 251-252.	10.7	18
24	Prognostic impact of Ki-67 labeling indices with 3 different cutoff values, histological grade, and nuclear grade in hormone-receptor-positive, HER2-negative, node-negative invasive breast cancers. <i>Breast Cancer</i> , 2015, 22, 141-152.	2.9	33
25	A pilot feasibility study for cisplatin plus S-1 for the treatment for advanced or recurrent cervical cancer. <i>Cancer Chemotherapy and Pharmacology</i> , 2013, 71, 1369-1374.	2.3	8
26	Extended trastuzumab therapy improves the survival of HER2-positive breast cancer patients following surgery and radiotherapy for brain metastases. <i>Molecular and Clinical Oncology</i> , 2013, 1, 995-1001.	1.0	10
27	An Analysis of Guidance for Proper Usage Documents for Oncology Drugs in Japan. <i>Pharmaceutical Medicine</i> , 2012, 26, 165-170.	1.9	0
28	Content Analysis of Oncology-Related Pharmaceutical Advertising in a Peer-Reviewed Medical Journal. <i>PLoS ONE</i> , 2012, 7, e44393.	2.5	3
29	Contrasting Prognostic Implications of Platelet-Derived Growth Factor Receptor- β and Vascular Endothelial Growth Factor Receptor-2 in Patients with Angiosarcoma. <i>Annals of Surgical Oncology</i> , 2011, 18, 2841-2850.	1.5	27
30	The notorious "drug lag" for oncology drugs in Japan. <i>Investigational New Drugs</i> , 2011, 29, 706-712.	2.6	45
31	A retrospective study of the impact of age on patterns of care for elderly patients with metastatic breast cancer. <i>Medical Oncology</i> , 2011, 28, 434-440.	2.5	2
32	Immunohistochemical expression of HER1, HER3, and HER4 in HER2-positive breast cancer patients treated with trastuzumab-containing neoadjuvant chemotherapy. <i>Journal of Surgical Oncology</i> , 2010, 101, 222-227.	1.7	17
33	Influence of Suboptimal Treatment in Patients with Mediastinal Primary Nonseminomatous Germ Cell Tumors. <i>Oncology</i> , 2010, 78, 34-39.	1.9	1
34	Factors That Affect the Duration of the Interval Between the Completion of Palliative Chemotherapy and Death. <i>Oncologist</i> , 2009, 14, 752-759.	3.7	41
35	Immunohistochemical expression of PTEN and phosphorylated Akt are not correlated with clinical outcome in breast cancer patients treated with trastuzumab-containing neo-adjuvant chemotherapy. <i>Medical Oncology</i> , 2009, 26, 344-349.	2.5	28
36	Prediction of response and prognostic factors for Ewing family of tumors in a low incidence population. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 389-395.	2.5	5

#	ARTICLE	IF	CITATIONS
37	Development and verification of a prediction model using serum tumor markers to predict the response to chemotherapy of patients with metastatic or recurrent breast cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2008, 134, 1199-1206.	2.5	12
38	Phase 1 trial of denosumab safety, pharmacokinetics, and pharmacodynamics in Japanese women with breast cancer-related bone metastases. <i>Cancer Science</i> , 2008, 99, 1237-1242.	3.9	78
39	Development and validation of diagnostic prediction model for solitary pulmonary nodules. <i>Respirology</i> , 2007, 12, 856-862.	2.3	49
40	Prediction of response to repeat utilization of anthracycline in recurrent breast cancer patients previously administered anthracycline-containing chemotherapeutic regimens as neoadjuvant or adjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2007, 103, 313-318.	2.5	4
41	Prognostic factors for malignant pericardial effusion treated by pericardial drainage in solid-malignancy patients. <i>Medical Oncology</i> , 2007, 24, 425-430.	2.5	15
42	FP therapy for controlling malignant ascites in advanced pancreatic cancer patients. <i>Hepato-Gastroenterology</i> , 2007, 54, 2383-6.	0.5	4
43	Diffuse large B-cell lymphoma presenting as a unilateral solitary round pulmonary hilar node infarction. <i>Respirology</i> , 2006, 11, 224-226.	2.3	3
44	Correlation of p53 and MIB-1 expression with both the systemic recurrence and survival in cases of phyllodes tumors of the breast. <i>Pathology Research and Practice</i> , 2006, 202, 705-712.	2.3	44
45	Tumor-marker analysis and verification of prognostic models in patients with cancer of unknown primary, receiving platinum-based combination chemotherapy. <i>Journal of Cancer Research and Clinical Oncology</i> , 2006, 132, 635-642.	2.5	12
46	Pro-gastrin-releasing peptide as a factor predicting the incidence of brain metastasis in patients with small cell lung carcinoma with limited disease receiving prophylactic cranial irradiation. <i>Cancer</i> , 2005, 104, 811-816.	4.1	20
47	Potential interactions between irinotecan and rifampin in a patient with small-cell lung cancer. <i>International Journal of Clinical Oncology</i> , 2004, 9, 206-9.	2.2	9
48	Fungal Infection in Neutropenic Patients in a Hospital during Construction. <i>Japanese Journal of Infectious Diseases</i> , 2002, 55, 126-7.	1.2	9